Boston, MA, United States of America

Megan Carty

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Eisai R&D Management Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Megan Carty. Retrieved from https://idiyas.com/inventor/megan-carty

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Megan Carty: Innovator in Pharmaceutical Research

Introduction

Megan Carty is a prominent inventor based in Boston, MA. She has made significant contributions to the field of pharmaceutical research, particularly in the development of novel compounds.

Latest Patents

Megan holds 1 patent for her work on PPARg modulators and methods of use. The patent discloses novel compounds of Formula (1) and pharmaceutically acceptable salts, along with pharmaceutical compositions containing these compounds and methods for their use.

Career Highlights

Megan is currently employed at Eisai R&D Management Co., Ltd., where she continues to advance her research in the pharmaceutical industry. Her innovative work has positioned her as a key player in her field.

Collaborations

Megan collaborates with talented professionals such as Stephanos Ioannidis and Hyelee Lee, contributing to a dynamic research environment.

Conclusion

Megan Carty's contributions to pharmaceutical research and her innovative patent work highlight her as a significant figure in the industry. Her ongoing efforts continue to pave the way for advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…